Frailty, defined as vulnerability to multiple stressors ([@CIT0001]), is a frequent geriatric condition. Nevertheless, its conceptualization, based on two major approaches: the phenotype model ([@CIT0002]) or an accumulation of deficits ([@CIT0003]), remains a challenge. Irrespective of the model employed, frailty predicts main adverse outcomes such as mobility loss, falling, disability, hospitalization, institutionalization, and mortality ([@CIT0004]), and results in considerable medical and public expenditure. Frailty is a continuum: from a prefrail stage to mild impairment without a total loss of function ([@CIT0005]). Due to its potential reversibility at early stages, it is vital to assess the individual's degree of frailty ([@CIT0006]). In fact, interventions to achieve healthy aging through prevention programs are currently priorities expressed by the World Health Organization (WHO) and recent European policies ([@CIT0007]).

Although frailty is a multidimensional concept embracing physical, psychological, and environmental factors, most intervention studies have focused only on a one-dimensional, biomedical perspective ([@CIT0008]). Rehabilitation models present satisfactory results in gait speed and improvement of the score in the short physical performance battery (SPPB) ([@CIT0009]), but report inconclusive effects on functional ability and well-being ([@CIT0010]).

A considerable number of protocols have been performed in institutions ([@CIT0011]), at individuals' homes ([@CIT0012]), and with a small sample size of community-dwelling older adults ([@CIT0013]). Other interventions have only encompassed strategies based on nutritional supplementation or hormones. They partially failed to decelerate the sarcopenia process, and revealed an unfavorable safety profile ([@CIT0014],[@CIT0015]). Protein intake alone or combined with physical activity is the main nonpharmacological modality that effectively stimulates muscle protein synthesis ([@CIT0016]).

Furthermore, elderly patients frequently present cognitive disorders (executive function, attention, processing speed), together with affected emotional and social domains, which may trigger a rapid decline. To date, however, the relationship between frailty and cognitive states remains unclear ([@CIT0017]). Cognitive impairment as a key element in frailty characterization has been widely debated ([@CIT0018]). Physical activity appears to enhance cognitive performance in risk patients and when combined with protein supplementation, although results are inconclusive ([@CIT0019]). Memory stimulation programs also lead to positive performance changes in older adults with mild cognitive impairment ([@CIT0020]).

Another fundamental and well-documented factor is polypharmacy ([@CIT0021]). It has been associated with high morbidity and mortality rates in frail, elderly individuals, due to adverse drug reactions, interactions, underuse, nonadherence, and inappropriate prescribing. Nevertheless, the Screening Tool of Older Person's potentially inappropriate Prescription (STOPP) and START guidelines offer a promising strategy to improve appropriate prescribing in the elderly adults ([@CIT0022]). Moreover, emerging studies dealing with frailty have begun to ascertain whether it could be slowed down or even reversed with multi-intervention clinical trials ([@CIT0011],[@CIT0023],[@CIT0024]) and have reported modest but encouraging outcomes.

The objective of our trial was to assess the effectiveness of a multifactorial intervention to modify frailty parameters: physical dimensions (muscle strength, elasticity, balance), cognitive performance, and polypharmacy in frail, elderly community-dwelling individuals. We carried out a 12-week multidisciplinary intervention involving clinicians, physiotherapists, speech therapists, and social workers, based on structured physical activity, diet supplementation, memory workshops, and medication review.

Methods {#s5}
=======

Study Design and Setting {#s6}
------------------------

A prospective, single-blind, parallel-group, pragmatic, randomized, multicenter, clinical trial was performed with an 18-month follow-up. Details of the methods have been previously published ([@CIT0025]). Trial registration: ClinicalTrials.gov NCT01969526.

The study was conducted at 8 primary health care centers and involved 352 community-dwelling adults aged older than 65 from different areas of Barcelona. Changes from baseline frailty measurements at enrollment were compared between the intervention (IG) and control group (CG) at the end of the intervention, and 18 months later.

Participants and Recruitment {#s7}
----------------------------

Inclusion criteria were: set gait time between 10 and 30 seconds in the Timed Get-up-and-Go test (TGUGT); scored Mini-Examination Cognitive of Lobo (MEC-35 Lobo) ≥18 points (no severe cognitive impairment); and Fried *modified* criteria. See [Supplementary Table 1](#sup1){ref-type="supplementary-material"} for further details.

Eligible participants were randomized 1:1 to the IG and CG. Sequence was concealed until the interventions were assigned. Baseline and outcome measurements were blinded to group assignment. Follow-up evaluations were conducted by blind, clinical researchers. [Figure 1](#F1){ref-type="fig"} describes the flow-diagram of participants.

![CONSORT diagram reflecting flow of study participants.](glx25901){#F1}

Intervention {#s8}
------------

Briefly, participants in the IG received a multidisciplinary multifactorial therapy, consecutively applied to each subject in groups of 16 participants: **Structured physical activity**, providing a well-established aerobics exercise program in each primary health care center, a 60-minute session twice a week on non-consecutive days for 6 weeks, conducted by physiotherapists.Intake of **1 hyperproteic nutritional shake** (Meritene Activ; Nestlé Health Science-NHS), which was taken daily for 6 weeks during the exercise training.**Memory workshops**, consisting of a 90-minute session twice a week, 12 sessions of practical exercises (written, oral, corporal, and musical), conducted by speech therapists from the Rehabilitation Unit.**Medication Review**, following STOPP criteria, with special focus on psychotropic drugs.

Control participants received the usual care. Both groups were also given counseling regarding dietary habits, lifestyle recommendations, and domestic hazards.

Outcome Variables {#s9}
-----------------

1.  Physical Dimension: a) SPPB, a standardized assessment tool of lower limb function (s*tanding balance*, r*epeated chair stands, gait speed).*b) Evaluation of upper extremities' strength by a handgrip dynamometer (HG).c) *Functional Reach Test* which measures standing balance and stretching.d) Unipodal Station Test which measures balance.

2.  **Neuropsychological Performance:** a) *Short and Medium-Term Verbal Memory.*b) *Animal Naming Test* which scores semantic verbal fluency category.c) *Evocation of words beginning with one explicit letter* which scores phonetic verbal fluency category.d) *Designation of famous people's names*, which scores phonological retrieval failure.e) *Verbal designation of images* which scores visual recognition memory.f) *Verbal abstraction of word pairs* which scores connection between verbal recognition memory and neuroprocessing mechanisms.

3.  **Medication.** Number of prescriptions.

See Supplementary Methods for further details.

Statistics {#s10}
----------

Outcome variables were assessed at baseline and at 3 and 18 months after randomization. Consistent with the protocol design, an intention-to-treat approach was employed. The incomplete cases were handled using the multiple imputation analysis by "mi impute pmm" procedure in Stata IC v12 statistical software. The estimates of the parameters for each imputed data set were combined using Rubin's rules ([@CIT0026]). Sensitivity analyses comparing complete cases versus multiple imputation analysis are shown in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}.

The change of each outcome during the follow-up was assessed by multilevel mixed-effects linear regression adjusted by age, gender, marital status, educational status, income, and baseline TGUG and MEC-35. Interaction terms between the intervention, gender, and age were also tested and none were statistically significant.

Standardized effect sizes were calculated as the mean difference between IG and CG, divided by the pooled standard deviation of CG and IG change ([@CIT0027]). Estimates were reported with corresponding 95% confidence intervals, and statistical significance was established as a *p* value less than .05.

Results {#s11}
=======

Between January 2013 and January 2015, participants were randomized to the multi-intervention (*n* = 176) or the control (*n* = 176) groups. The main characteristics of our study sample according to randomization group are presented in [Table 1](#T1){ref-type="table"}. A total of 265 participants (75.3%) were female, mean age 77.3 years, nearly half of them living alone (47.2%), The baseline features of the two groups were similar in terms of inclusion criteria, age, sex, civil status, cohabitation, comorbidity, and biological variables, including nutritional, functional, and mental performance, as shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

###### 

Baseline Characteristics by Treatment Group

                                                Control Group (*n* = 176)   Intervention Group (*n* = 176)   *p* Value   
  --------------------------------------------- --------------------------- -------------------------------- ----------- ------
  Gender, *n* (%)                               Male                        45 (25.6)                        42 (23.9)   .711
  Female                                        131 (74.4)                  134 (76.1)                                   
  Age, years, mean (*SD*)                       77.4 (7.7)                  77.2 (6.8)                       .770        
  Living alone, *n* (%)                         83 (47.2)                   83 (47.2)                        1.00        
  Marital Status, *n* (%)                       Single                      23 (13.1)                        22 (12.5)   .884
  Widowed                                       76 (43.2)                   80 (45.5)                                    
  Married                                       67 (38.1)                   67 (38.1)                                    
  Divorced                                      10 (5.7)                    7 (4.0)                                      
  Educational status, *n* (%)                   Unfinished studies          67 (38.1)                        78 (44.3)   .037
  Primary school                                80 (45.5)                   60 (34.1)                                    
  Secondary school                              25 (14.2)                   25 (14.2)                                    
  University degree                             4 (2.3)                     13 (7.4)                                     
  Falls, previous year, *n* (%)                 59 (33.5)                   57 (32.4)                        .821        
  Hospital admissions, previous year, *n* (%)   33 (18.8)                   40 (22.7)                        .357        
  MEC-35 Lobo score, mean (*SD*)                30.6 (4.1)                  31.2 (3.2)                       .135        
  Lawton & Brody Scale, mean (*SD*)             6.5 (1.9)                   6.6 (1.76)                       .660        
  Barthel Index, mean (*SD*)                    96.1 (7.5)                  96.0 (6.2)                       .938        
  Number of drugs/day, mean (*SD*)              6.6 (3.8)                   7.7 (3.2)                        .004        
  Charlson Index, mean (*SD*)                   1.3 (1.5)                   1.5 (1.6)                        .203        
  TGUGT, mean (*SD*)                            14.5 (4.9)                  15.0 (4.9)                       .368        
  Frailty criteria, *n* (%)^a^                  Prefrail                    44 (25.0)                        45 (25.6)   .900
  Frail                                         132 (75.0)                  131 (74.4)                                   

*Note*: *n* = number of subjects; SD = Standard deviation; TGUGT = Timed get up and go test.

^a^Adapted from ref. ([@CIT0002]).

At the 12-week evaluation, follow-up data from 173 participants in the IG and 174 in the CG were available for analysis. At 18 months, 148 and 119 participants were reassessed, respectively (76% of the baseline sample, see [Figure 1](#F1){ref-type="fig"}). The participants that were not assessed at the 18-month interview (*n* = 85) were similar to the interviewed group in terms of gender and baseline inclusion criteria, but 2 years older. Sixty-seven percent of the missing data group belonged to the CG, but there were no differences in baseline characteristics between IG and CG in terms of age, gender, inclusion criteria, and SPPB.

After the intervention, there were significant improvements in all major variables related to frailty measures in the IG while in the CG the result was inverse. There was a significant average increase of the difference between groups in SPPB score means adjusted by potential confounders at 3 and 18 months: 1.58 and 1.36 (*p* \< .001), respectively. Standardized effect sizes at 3 and 18 months were rated as very large (1.18) and moderate (0.69), respectively.

Similar results were seen in strength of upper extremities and balance measurements, and in the mental performance battery, with also significant mean improvements between groups and medium and large standardized effect size indices at 3 months, but small at 18 months. All evaluated changes in physical and cognitive performance at 3 and 18 months are shown in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. Percentage of polypharmacy decreased 9.6% in the IG, but increased 4.5% in the CG after the intervention. Prescribed benzodiazepines decreased in the IG compared to the CG (−0.011 vs +0.023) but did not reach statistical significance.

###### 

Change in Physical Performance Measures and Prescriptions Between Intervention and Control Groups at 3 and 18 mo

                               Control Group *N* = 176   Intervention Group *N* = 176   Adjusted Mean Difference (95% CI) Between Groups (IG-CG)^a,b^            
  ---------------------------- ------------------------- ------------------------------ --------------------------------------------------------------- -------- ------
  Physical tests                                                                                                                                                 
  SPPB (range 0--12)                                                                                                                                             
   Pre-I                       7.3 (2.4)                 7.1 (2.3)                                                                                      \<.001   1.18
   Post-3 mo                   6.8 (2.3)                 8.1 (2.2)                      1.58 (1.29--1.86)                                                        
   Post-18 mo                  7.0 (2.6)                 8.1 (2.3)                      1.36 (0.89--1.83)                                               \<.001   0.69
  Handgrip (kg)                                                                                                                                                  
   Pre-I                       16.5 (7.4)                16.5 (7.7)                                                                                     \<.001   1.12
   Post-3 mo                   15.8 (6.9)                18.6 (7.7)                     2.86 (2.32--3.41)                                                        
   Post-18 mo                  15.7 (7.8)                18.2 (7.9)                     2.49 (1.09--3.89)                                               .001     0.41
  Functional reach (cm)                                                                                                                                          
   Pre-I                       82.2 (9.3)                80.7 (10.1)                                                                                    \<.001   0.96
   Post-3 mo                   80.7 (8.8)                83.5 (9.3)                     4.34 (3.35--5.32)                                                        
   Post-18 mo                  79.7 (10.5)               82.7 (10.7)                    4.52 (2.32--6.72)                                               \<.001   0.47
  Unipodal station (seconds)                                                                                                                                     
   Pre-I                       8.2 (9.7)                 6.9 (8.0)                                                                                      \<.001   0.75
   Post-3 mo                   7.3 (9.2)                 9.6 (9.1)                      3.58 (2.57--4.59)                                                        
   Post-18 mo                  7.7 (9.0)                 9.3 (8.7)                      2.98 (1.11--4.84)                                               .002     0.37
  Number of drugs/day                                                                                                                                            
   Pre-I                       6.6 (3.8)                 7.7 (3.2)                                                                                      \<.001   0.99
   Post-3 mo                   7.2 (4.0)                 6.9 (3.2)                      −1.39 (−1.69--−1.10)                                                     
   Post-18 mo                  7.5 (4.1)                 7.5 (3.4)                      −1.09 (−1.71--−0.47)                                            .001     0.37

*Note*: CG = Control group; CI = Confidence interval; I = Intervention; IG = Intervention group; *N* = Number; SD = Standard deviation; SES = Standardized effect size; SPPB = Short physical performance battery.

^a^Intention to treat analyses using missing value imputation. ^b^Multilevel mixed-effects linear regression adjusted by age, gender, marital status, educational status, income, MEC-35 Lobo, TGUGT. ^c^Cohen's *d*.

###### 

Change in Neuropsychological Performance Measures Between Intervention and Control Groups at 3 and 18 mo

                                                            Control Group *N* = 176   Intervention Group *N* = 176   Adjusted Mean Difference (95% CI) Between Groups (IG-CG)^a,b^            
  --------------------------------------------------------- ------------------------- ------------------------------ --------------------------------------------------------------- -------- ------
  **Short-Term Verbal Memory (range 0--21**)                                                                                                                                                  
   Pre-I                                                    5.6 (2.5)                 5.3 (2.7)                                                                                      \<.001   0.67
   Post-3 mo                                                5.0 (2.2)                 5.9 (2.7)                      1.19 (0.82--1.57)                                                        
   Post-18 mo                                               5.0 (2.4)                 5.3 (2.2)                      0.67 (0.13--1.21)                                               .015     0.28
  **Medium-Term Verbal Memory: Retest** (range 0--21)                                                                                                                                         
   Pre-I                                                    4.0 (2.3)                 3.9 (2.4)                                                                                      \<.001   0.71
   Post-3 mo                                                3.8 (1.9)                 4.9 (2.4)                      1.11 (0.78--1.44)                                                        
   Post-18 mo                                               3.4 (2.2)                 4.0 (2.1)                      0.69 (0.12--1.21)                                               .016     0.31
  **Animal Naming Test**                                                                                                                                                                      
   Pre-I                                                    15.0 (5.1)                15.2 (4.6)                                                                                     \<.001   0.77
   Post-3 mo                                                14.4 (4.9)                16.6 (4.8)                     2.01 (1.46--2.56)                                                        
   Post-18 mo                                               14.7 (5.3)                15.9 (4.7)                     1.05 (0.12--1.97)                                               .026     0.26
  **Evocation of words**                                                                                                                                                                      
   Pre-I                                                    19.1 (7.9)                19.4 (8.5)                                                                                     \<.001   0.93
   Post-3 mo                                                17.8 (7.1)                21.9 (8.8)                     3.64 (2.81--4.47)                                                        
   Post-18 mo                                               18.3 (7.9)                20.8 (8.0)                     2.10 (0.50--3.71)                                               .010     0.32
  **Designation of famous people's names**                                                                                                                                                    
   Pre-I                                                    19.8 (6.1)                20.8 (6.2)                                                                                     \<.001   0.67
   Post-3 mo                                                19.1 (5.8)                22.1 (6.1)                     1.92 (1.31--2.53)                                                        
   Post-18 mo                                               20.7 (6.3)                22.4 (6.2)                     0.71 (−0.41--1.83)                                              .212     0.15
  **Verbal designation of images** (number in ≤3 seconds)                                                                                                                                     
   Pre-I                                                    13.1 (1.2)                13.1 (1.4)                                                                                     \<.001   0.59
   Post-3 mo                                                12.8 (1.6)                13.5 (1.1)                     0.71 (0.46--0.97)                                                        
   Post-18 mo                                               12.9 (1.6)                13.4 (1.2)                     0.53 (0.20--0.86)                                               .002     0.36
  **Verbal abstraction of word pairs**                                                                                                                                                        
   Pre-I                                                    3.5 (1.4)                 3.5 (1.5)                                                                                      \<.001   0.35
   Post-3 mo                                                3.2 (1.3)                 3.6 (1.5)                      0.40 (0.16--0.65)                                                        
   Post-18 mo                                               2.7 (1.5)                 3.1 (1.6)                      0.46 (0.40--0.89)                                               .032     0.25

*Note*: CG = Control group; CI = Confidence interval; I = Intervention; IG = Intervention group; *N* = Number; SD = Standard deviation; SES = Standardized effect size; SPPB = Short physical performance battery.

^a^Intention to treat analyses using missing value imputation. ^b^Multilevel mixed-effects linear regression adjusted by age, gender, marital status, educational status, income, MEC-35 Lobo, TGUGT. ^c^ Cohen's *d*.

In the IG, the mean number of sessions attended was 13, out of a total of 24 in the program. [Figure 2](#F2){ref-type="fig"} shows mean change in the physical and cognitive variables at 3 months according to the range of sessions attended.

![Mean change score (95% CI) in outcome variables at 3 months, stratified by total number of sessions attended in the intervention group. Note: 0 = no sessions attended; 1 = 1--12 sessions; 2 = 13--24 sessions; SPPB = Short physical performance battery; HG = Hand grip; F.R. = Functional reach; U.POD = Unipodal station; R.ST = Short-term verbal memory; RET = Medium-term verbal memory; ANIM = Animal naming test; PW = Evocation of words beginning with P; FACES = Designation of people's names; IMAG = Designation of images; ABSTR = Verbal abstraction of pairs.](glx25902){#F2}

Finally, attendance at the educational sessions was 48% in the CG and 52% in the IG.

Discussion {#s12}
==========

Our main finding is that a combined intervention that includes physical activity plus protein intake, along with memory workshops and medication review, improved functional and cognitive performance in frail/prefrail, community-dwelling, older adults at 12 weeks from commencing the intervention. The effect was significantly maintained up to at least 18 months. To the best of our knowledge, this is the first quadruple interventional trial performed to improve different frailty domains.

There is considerable evidence regarding the positive short and medium term impact of physical activity on strength, balance, and falls in moderately frail, elderly community-dwellers ([@CIT0028],[@CIT0029]). Consistent with previous studies, our results in the IG showed a clear improvement in mobility, balance (better SPPB score), stretching, and muscle strength (handgrip), showing also sustained effects at long term.

Nutritional interventions with protein and energy supplementation have also reported good results in physical function for elderly people at risk of malnutrition ([@CIT0030]). Our study revealed positive physical benefits for protein-calorie and micronutrient intake supplementation in association with physical activity, irrespective of basal nutritional status. However, further studies are required to determine whether this finding is explained by an adding effect or attributable to individual variables of dietary intake. As far as we are aware, only one study has demonstrated that nutritional supplementation alone can reduce frailty ([@CIT0031]).

Frailty and cognition interact in the cycle leading to disability and dependency ([@CIT0032]), and interventions in cognitive areas should be encouraged to prevent or even reverse further physical decline ([@CIT0033]). It has also been reported that physical exercise training improves cognitive functioning and psychological well-being in frail, older adults ([@CIT0034]). In agreement with these studies, we found that cognitive training program targeting short and medium-term memory, attention, and executive functions, along with physical training, had an effect on cognition (significant changes in memory and abstraction tests), and also improved motor balance and strength. Transference of cognitive remediation effects to mobility, as described by other authors ([@CIT0033]), could be related to an indirect enhancement of social and functioning abilities among the IG participants.

An association between polypharmacy and frailty has been reported ([@CIT0035]), and polypharmacy itself is considered to be a risk factor for negative outcomes (falls, cognitive impairment, mortality). As expected, our review of all medicated subjects led to a reduction of prescriptions (an average of one drug per subject, especially psychotropic medication). In concurrence with recent studies ([@CIT0036]), the reduction was more effective in patients receiving polypharmacy than those who were not.

The combination of complex strategies is nowadays considered the optimum approach to improve frailty standards of care beyond current clinical practice ([@CIT0037]). Recently, a comprehensive review ([@CIT0038]) highlighted promising results related to these individually- tailored, multidisciplinary interventions, which appear to produce short-medium term benefits in decelerating frailty.

As previously stated, this is the first randomized controlled trial with intention-to-treat analysis which adds the novelty of concomitant cognition and medication interventions and their postevaluation. Our multistrategy resulted in a clear improvement in mobility and strength performance tests, enhancement of mental performance, and reduction of polypharmacy, with marked effect sizes for most comparisons at 3 months follow-up. Moreover, despite the fact that the intervention was not maintained beyond 3 months, significant improvements were still observed at 18 months. In contrast, in a study conducted in Sydney, the benefit of a multidomain intervention was not evident at 12 weeks follow-up and only apparent at 12 months ([@CIT0023]).

Frailty is globally considered to be reversible and preventable in its initial phases ([@CIT0006]), and prefrailty is a field of growing interest. Thus, identifying the target population for enrollment in programs addressing this issue is a challenge. Based on gait speed and balance (TGUGT), our study tackled a full segment of community-dwellers who ranged from prefrail to medium-frail when applying Fried criteria. We found similar improvements in all the patients' parameters, suggesting that triage through simple performance measures such as TGUGT could be sufficient to enroll the elderly in potentially effective activities.

Following the guidelines of the *Frailty Working Group* ([@CIT0039]), we carried out physical assessment through several complementary tests the results of which were partly self-reported and partly performance-based. Nevertheless, the primary outcomes (the SPPB, neurocognitive tests, and prescriptions) were objective measures that should reduce observer bias.

In contrast to other studies ([@CIT0030]), our intervention was designed as a global, combined approach. Thus, the individual effect of protein supplementation and memory workshops could not be analyzed. Another limitation could be that, as nutritional parameters did not form part of the inclusion criteria, it is difficult to assess the real effect of the protein intake in the IG.

Intention-to-treat analysis was conducted to assess final outcomes, and missing values imputation and sensitivity analyses were performed using the recommended strategy ([@CIT0026]). Although at 12 weeks only five individuals were not contacted, at 18 months 24% of the sample could not be reassessed (mainly from the CG) either due to worse health status or lacking motivation to participate in the reassessment. Nevertheless, bias caused by differential losses seems unlikely as baseline characteristics are similar between IG and CG in the complete data and missing data groups. Full attendance at the exercise activities and memory workshops was not achieved by most participants: mean attendance was 13 out of 24 sessions. We found a dose-respond pattern between number of attended sessions and improvements in physical outcomes, although this pattern was inconsistent in the cognitive ones ([Figure 2](#F2){ref-type="fig"}).

As with the frailty phenotype, baseline characteristics were not likely to affect the intensity of the effect we found, and the final model was adjusted to those characteristics. Neither was any gender interaction observed, the effect was similar in both men and women.

There were no adverse events. Occasional absences from the sessions were due to external social events or acute-short illness unrelated to the intervention.

The intervention is readily transferable to routine clinical practice in integrated, elderly, healthcare settings with specific, clinically experienced teams. Indeed, it would be of interest to conduct trials testing the intervention in different environments, where our experience could be easily adapted. In this regard, the myriad physical, cognitive, and social activities taking place in most communities, if properly designed and conducted, could easily replace the more supervised and controlled interventions performed in trials. Moreover, the economic burden of falls, hospital admissions, and disability in the elderly is greater than the cost-effective specific interventions that could be carried out ([@CIT0040]). Adherence to interventions may be a handicap. Nevertheless, although participants in the IG did not attend all the activities, we still found high adherence mainly due mainly to their enjoying social interaction in historically proactive districts. Although the intervention was limited to 3 months, the enhancement of community networks may also have added to the sustained long-term improvement found in the IG.

Conclusions {#s13}
===========

The results of this study provide further evidence regarding the beneficial effect for frail, elderly individuals of a multifactorial intervention including exercise training (combining functional, resistance, and aerobic exercise modes), protein intake, cognition workshops, and medication review as a global strategy to reduce loss of autonomy and its risk factors. Our findings show the feasibility of identifying frail/prefrail individuals through simple performance measures in primary care settings, and how a multidisciplinary, coordinated care approach improves function and cognition in elderly community-dwellers. Our results, the long term changes in frailty parameters, and the social empowerment achieved, may lead to the prevention of future negative outcomes in the frail population. The scalability of our intervention encourages future collaboration with community organizations in elderly-friendly cities.

Availability of Data and Material {#s15}
=================================

The datasets used are available from the corresponding author on reasonable request.

Funding {#s16}
=======

This study was supported by ISCIII, Ministry of Economy and Competitiveness, Spain, Technical, Scientific and Innovation Research National Plan 2008--2011, cofunded with European Union ERDF funds; PI12/01503.

Conflict of Interest {#s17}
====================

None reported.

Supplementary Material
======================

###### 

Click here for additional data file.
